618428-58-3

Basic information

• Product Name: 3-{3(S)-[N-(N-methyl-1,2-dihydroisoquinolin-5-yloxyacetyl)-l-valinyl]amino-2(S)-hydroxy-4-phenylbutanoyl}-N-(tert-butyl)thiazolidine-4(R)-carboxamide
• Synonyms: 3-{3(S)-[N-(N-methyl-1,2-dihydroisoquinolin-5-yloxyacetyl)-l-valinyl]amino-2(S)-hydroxy-4-phenylbutanoyl}-N-(tert-butyl)thiazolidine-4(R)-carboxamide
• CAS NO: 618428-58-3
• Molecular Weight: 665.854
• Mol File: 618428-58-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-{3(S)-[N-(N-methyl-1,2-dihydroisoquinolin-5-yloxyacetyl)-l-valinyl]amino-2(S)-hydroxy-4-phenylbutanoyl}-N-(tert-butyl)thiazolidine-4(R)-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-{3(S)-[N-(N-methyl-1,2-dihydroisoquinolin-5-yloxyacetyl)-l-valinyl]amino-2(S)-hydroxy-4-phenylbutanoyl}-N-(tert-butyl)thiazolidine-4(R)-carboxamide(618428-58-3)
• EPA Substance Registry System: 3-{3(S)-[N-(N-methyl-1,2-dihydroisoquinolin-5-yloxyacetyl)-l-valinyl]amino-2(S)-hydroxy-4-phenylbutanoyl}-N-(tert-butyl)thiazolidine-4(R)-carboxamide(618428-58-3)

Safety Data

• Hazardous Substances Data: 618428-58-3(Hazardous Substances Data)

Upstream product

• 156880-90-9 (R)-N-tert-butyl-3-[(2S,3S)-2-hydroxy-3-[(S)-2-(5-isoquinolinyloxyacetyl)amino-3-methylbutanoyl]amino-4-phenylbutanoyl]-1,3-thiazolidine-4-carboxamide 

Relevant articles and documents

Brain delivery of HIV protease inhibitors

To overcome the problems of peptidomimetic drug delivery to the specific organs, the use of dihydropyridine ? pyridinium chemical delivery systems to deliver peptides to the brain is considered in this work. An HIV protease inhibitor lead compound; KNI 279 was selected for the study. The N-alkylated dihydroisoquinoline derivatives of KNI-279 were synthesized and tested for their ability to be oxidized by brain homogenate and showed good results with reasonable half-life times specially for the N-alkoxycarbonyl-methyl derivative 8. The in-vivo distribution of compound 8 proved the brain delivery and locked in property of HIV PR inhibitors in the brain. All the prepared compounds (both quaternary and dihydro derivatives) showed between 51 and 86% HIV PR inhibitory activity compared to the parent compound.